|1.||Chang, Chawnshang: 102 articles (11/2015 - 02/2002)|
|2.||Yeh, Shuyuan: 57 articles (11/2015 - 02/2002)|
|3.||Sobue, Gen: 49 articles (12/2015 - 08/2002)|
|4.||Katsuno, Masahisa: 40 articles (12/2015 - 08/2002)|
|5.||Scher, Howard I: 39 articles (11/2015 - 05/2002)|
|6.||Rennie, Paul S: 36 articles (05/2016 - 05/2002)|
|7.||Tindall, Donald J: 36 articles (11/2015 - 01/2002)|
|8.||Tilley, Wayne D: 35 articles (05/2016 - 12/2002)|
|9.||Balk, Steven P: 34 articles (03/2015 - 07/2002)|
|10.||Culig, Zoran: 30 articles (02/2016 - 05/2002)|
|1.||Prostatic Neoplasms (Prostate Cancer)
09/29/2015 - "In the TRAMP transgenic model of spontaneous prostate cancer, MVA-TWIST/TRICOM alone significantly improved survival, and when combined with the androgen receptor antagonist enzalutamide, the vaccine further improved survival. "
07/01/2012 - "Castrate resistant prostate cancer is a disease state which, counterintuitively, can be successfully treated with additional therapy directed at inhibition of androgen synthesis and/or interfering with the activity of the androgen receptor. "
07/01/2006 - "Based on our in vivo model, androgen is beneficial for the treatment of androgen-independent androgen receptor-rich prostate cancer and modulation of LXR signaling may be a potentially useful therapy for prostate cancer."
01/01/1996 - "The observation, therefore, that antiandrogen withdrawal can be beneficial for some prostate cancer patients, might be understood in the light of an altered ligand responsiveness of mutant androgen receptors."
04/15/2007 - "In vitro studies were done on a panel of prostate cancer cell lines to understand the molecular basis of combination therapy, and we found that the combination was more effective in the inhibition of cell viability and induction of apoptosis in LNCaP and C4-2b cells (androgen receptor positive) but not in PC-3 cells. "
07/01/1999 - "In pharmacological studies using rats and other subjects, the product showed excellent affinity with androgen receptors and was found to be anti-androgen active and effective against tumors, and so clinical trials have begun. "
12/01/2004 - "Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor."
06/01/2015 - "We conducted the first study to evaluate these associations by tumor androgen receptor (AR) status. "
01/01/2015 - "In this study, a polymerase chain reaction-based canine XCIP analysis of the androgen receptor (AR) gene was applied for the assessment of cell clonality in canine hematopoietic tumors. "
08/01/2014 - "This study identifies PCAT29 as the first androgen receptor-repressed lncRNA that functions as a tumor suppressor and that its loss may identify a subset of patients at higher risk for disease recurrence. "
|3.||Breast Neoplasms (Breast Cancer)
03/01/2014 - "Disease-free survival was significantly better in androgen receptor-positive triple-negative breast cancer, with a trend for improved overall survival. "
11/01/2014 - "However, the recent clinical development of selective androgen receptor modulators with greatly improved side-effect profiles has renewed interest in androgen agonist therapy for advanced breast cancer. "
11/01/2014 - "Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer."
12/15/1989 - "Improved measurement of androgen receptors in human breast cancer."
01/01/2015 - "Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial."
|4.||X-Linked Bulbo-Spinal Atrophy (Syndrome, Kennedy)
03/01/2001 - "Conversely, enhancement of chaperone activity may be beneficial in disorders of protein misfolding, as in the case of androgen receptor aggregates found in Spinal and Bulbar Muscular Atrophy."
11/01/2013 - "Clearance of the mutant androgen receptor in motoneuronal models of spinal and bulbar muscular atrophy."
05/09/2007 - "CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model."
03/01/2007 - "ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor."
11/01/1996 - "[Study of androgen receptor expression and neuronal vulnerability in X-linked spinal and bulbar muscular atrophy]."
10/20/2007 - "--Hirsutism in women with PCOS, or without measurable changes in plasma androgen levels, can be treated with drugs either inhibiting ovarian or adrenal androgen production, blocking androgen receptors or inhibiting 5alpha-reductase in the hair follicle. "
07/01/2006 - "Consistently, drugs inhibiting androgen receptor binding not only are an effective tool in hirsutism treatment but also show favorable effects on body composition and metabolic features of these women."
03/01/2006 - "In patients with idiopathic hirsutism, a preferential methylation of the of shorter androgen receptor (AR) alleles was hypothesized to be responsible for the abnormal hair growth. "
04/01/2000 - "The role of the CAG repeat polymorphism in the androgen receptor gene and of skewed X-chromosome inactivation, in the pathogenesis of hirsutism."
03/01/1999 - "Idiopathic hirsutism may result from an increase in the androgen receptor (AR)-mediated sensitivity of the hair follicle. "
|7.||Steroid 17-alpha-Hydroxylase (17 alpha Hydroxylase)
|8.||Androgen Antagonists (Antiandrogens)
|10.||Proteins (Proteins, Gene)
|2.||Drug Therapy (Chemotherapy)
|3.||Prostatectomy (Retropubic Prostatectomy)
|5.||Hair Removal (Depilation)